154 related articles for article (PubMed ID: 23743194)
1. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228.
Choudhary S; Sood S; Wang HC
Biochem Biophys Res Commun; 2013 Jun; 436(2):325-30. PubMed ID: 23743194
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death.
Choudhary S; Wang KK; Wang HC
Mol Carcinog; 2011 Mar; 50(3):215-9. PubMed ID: 21344509
[TBL] [Abstract][Full Text] [Related]
4. Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.
Choudhary S; Rathore K; Wang HC
J Cancer Res Clin Oncol; 2011 Mar; 137(3):471-80. PubMed ID: 20473523
[TBL] [Abstract][Full Text] [Related]
5. FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death.
Choudhary S; Rathore K; Wang HC
Anticancer Drugs; 2010 Oct; 21(9):831-40. PubMed ID: 20700043
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
[TBL] [Abstract][Full Text] [Related]
7. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
[TBL] [Abstract][Full Text] [Related]
8. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.
Park BH; Lim JE; Jeon HG; Seo SI; Lee HM; Choi HY; Jeon SS; Jeong BC
Oncotarget; 2016 Sep; 7(39):63870-63886. PubMed ID: 27564099
[TBL] [Abstract][Full Text] [Related]
9. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
10. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells.
Pak JH; Choi WH; Lee HM; Joo WD; Kim JH; Kim YT; Kim YM; Nam JH
Cancer Invest; 2011 Jan; 29(1):21-8. PubMed ID: 21166495
[TBL] [Abstract][Full Text] [Related]
11. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell.
Periasamy VS; Alshatwi AA
Basic Clin Pharmacol Toxicol; 2013 Jun; 112(6):374-84. PubMed ID: 23145928
[TBL] [Abstract][Full Text] [Related]
12. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
[TBL] [Abstract][Full Text] [Related]
13. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
[TBL] [Abstract][Full Text] [Related]
14. Emetine dihydrochloride: a novel therapy for bladder cancer.
Foreman KE; Jesse JN; Kuo PC; Gupta GN
J Urol; 2014 Feb; 191(2):502-9. PubMed ID: 24045224
[TBL] [Abstract][Full Text] [Related]
15. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
16. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Matsui Y; Watanabe J; Ding S; Nishizawa K; Kajita Y; Ichioka K; Saito R; Kobayashi T; Ogawa O; Nishiyama H
BJU Int; 2010 Feb; 105(4):558-64. PubMed ID: 19583730
[TBL] [Abstract][Full Text] [Related]
17. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin‑resistant bladder tumor cell line.
Lee YJ; Lee S; Ho JN; Byun SS; Hong SK; Lee SE; Lee E
Oncol Rep; 2014 Nov; 32(5):1803-8. PubMed ID: 25175462
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
